<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00343226</url>
  </required_header>
  <id_info>
    <org_study_id>CCHI621ABE02</org_study_id>
    <nct_id>NCT00343226</nct_id>
  </id_info>
  <brief_title>An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in &quot;de Novo&quot; Liver Transplantation.</brief_title>
  <official_title>An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in &quot;de Novo&quot; Liver Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The objectives of the study are:To compare the renal function of a quadruple&#xD;
      immunosuppressive regimen (including basiliximab in combination with an optimized&#xD;
      cyclosporine dose during the first weeks post-transplantation, mycophenolate mofetil and&#xD;
      corticosteroids) versus a standard triple therapy regimen (including cyclosporine standard&#xD;
      dose, mycophenolate mofetil and corticosteroids)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function (i.e. glomerular filtration rate) at 12 months post-transplantation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of rejection episodes before 6 and 12 months post-transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of death, graft loss or retransplantation before 6 and 12 months post-transplantation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of initial hospitalization and number or hospital re-admissions.</measure>
  </secondary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Liver Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  First cadaveric liver transplant&#xD;
&#xD;
          -  ABO identical or compatible graft&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Multiple organ transplant&#xD;
&#xD;
          -  renal impairment defined as glomerular filtration rate (GFR) &lt; 30 ml/min&#xD;
&#xD;
          -  Fulminant liver failure&#xD;
&#xD;
        Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>June 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2006</study_first_posted>
  <last_update_submitted>August 24, 2010</last_update_submitted>
  <last_update_submitted_qc>August 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Novartis</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Basiliximab, transplantation, liver, renal function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Basiliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

